A Phase IIb, Double-blind, Parallel Group, Multi-center, Dose-finding Study to Investigate the Efficacy and Safety of 4 Doses of MP-513 When Added to Ongoing Metformin Monotherapy in Subjects With Type 2 Diabetes Mellitus, With an Open Label Extension.
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2016
At a glance
- Drugs Teneligliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 10 Jun 2017 Biomarkers information updated
- 06 Nov 2012 Planned number of patients changed from 400 to 448.
- 16 Dec 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.